Description: Baylor College of Medicine is one of 29 sites in the U.S. participating in this study. Insulin has multiple functions in the brain and dysregulation of insulin is known to occur in brain of Alzheimer patients. In a small exploratory trial lasting four months administration of intranasal insulin seemed to improve memory in persons with Alzheimer’s disease (AD) or mild cognitive impairment (MCI) without affecting plasma insulin or glucose levels. This study will evaluate the use of intranasal insulin on memory functioning in adults with mild stage AD or memory loss due to MCI over a 12 month period of time compared with placebo. There will be a six-month open label period at the end of the study in which all participants will receive intranasal insulin therapy.

Eligibility: Men or women between age 55 to 85 with a diagnosis of memory loss due to MCI or mild AD and stable medical conditions for three months prior to enrollment may be eligible. They must have a partner or caregiver available to attend most clinic appointments, and the partner or caregiver must be willing to supervise drug administration twice a day.

For more information, please contact Sydney O'Connor at (713) 798-8329 or